Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 2 (2)

Trial Status

Enrolling By Invitation1
Unknown1
Not Yet Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07310069Phase 2Enrolling By InvitationPrimary

Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer

NCT06591650Phase 2Not Yet RecruitingPrimary

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

NCT05493956Not ApplicableUnknownPrimary

A Randomised Study of Consolidation CTRT Versus Observation After First Line Chemotherapy in Advanced Gallbladder Cancer

Showing all 3 trials

Research Network

Activity Timeline